Eli Lilly and Incyte said the U.S. Food and Drug Administration didn’t approve their new drug application for a rheumatoid arthritis treatment that some analysts estimate could generate more than $2 billion in annual sales.
from WSJ.com: US Business http://ift.tt/2pjXM0k
via IFTTT
No comments:
Post a Comment